THE ADVANTAGE OF INTERMITTENT HGH THERAPY IN PATIENTS WITH ISOLATED AND COMBINED HGH DEFICIENCY

A. Pertzelan,R. Kauli,S. Assa,Z. Laron,
DOI: https://doi.org/10.1203/00006450-197508000-00136
IF: 3.953
1975-08-01
Pediatric Research
Abstract:Out of 46 patients treated by an intermittent HGH regime, 5 pts. with isol. HGH deficiency (IGHD) and 5 pts. with panhypopituitarism (CGHD) are presented. HGH was administered thrice weekly, 1–3 mg/injection, in courses of 3–14 months duration interspaced by intervals of 2–15 months. The patients received from 3–6 courses over a period of 2 3/12–6 3/12 years. This therapeutic schedule was found to be effective and in contradistinction to the continuous therapeutic schedule there was no progressive decline in growth-velocity. The patients with IGHD were found to respond better than those with CGHD, both in the first course as well as in consecutive courses. When compared to a long-term continuous therapeutic schedule (Table), our regime led to same growth achievement, saving the hormone which is scarce in its availability.
What problem does this paper attempt to address?